Trial Profile
A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- Acronyms KASTT001
- 23 May 2018 Status changed from recruiting to completed.
- 06 Dec 2016 New trial record